Opendata, web and dolomites

SAFER SIGNED

Selective Agonists For Serotonin Receptors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SAFER project word cloud

Explore the words cloud of the SAFER project. It provides you a very rough idea of what is the project "SAFER" about.

smes    ample    complementarity    lund    protein    mechanisms    ht2a    phd    drugs    giving    crystallography    crystallographic    crystals    interpret    seek    advantage    first    esrs    ligands    sustainability    guide    primary    cross    cns    selectivity    generate    job    subsequently    receptors    sweden    receptor    structures    molecular    biased    databases    complementary    opportune    innovation    fundamental    safer    society    hallucinogens    signalling    world    models    experiments    max    business    transferrable    expertise    demand    few    competitive    disorders    basic    data    skills    market    students    biological    mechanistic    worldwide    building    obtain    active    location    commercial    construct    pharmacology    move    intersectoral    arming    groups    resource    gpcrdb    understand    crystal    computational    scientific    coupled    timing    train    community    serotonin    gain    treatments    university    pharmaceuticals    synchrotron    industry    interdisciplinary    mastered    insights    translate    ultimate    services    public    therapeutic   

Project "SAFER" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.safer-itn.eu/
 Total cost 1˙286˙630 €
 EC max contribution 1˙286˙630 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-EID
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 290˙081.00
2    SAROMICS BIOSTRUCTURES AB SE (Lund) participant 512˙670.00
3    ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE UA (KYIV) participant 483˙878.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

SAFER will train 5 ESRs, PhD students, to obtain ample scientific, business and transferrable skills, arming them with the expertise to translate knowledge into products and services with importance for European industry and society. All ESRs will first train together at one university to develop complementary skills and basic research data; and subsequently move to two SMEs for applied and commercial research.

The ultimate scientific goal for the SAFER program is to gain molecular understanding and improve selectivity in treatments of CNS-related disorders. This will be done through an interdisciplinary and intersectoral approach, building on a strong complementarity between partners, with a particular focus on the serotonin 5-HT2A receptor – the primary target for many pharmaceuticals and hallucinogens. SAFER will generate and cross-interpret pharmacology and crystallographic data, and construct computational mechanistic models and databases that can explain and guide its experiments. Thus, SAFER will gain new insights into molecular mechanisms that are fundamental to understand the biological and therapeutic effects, and to develop safer drugs. SAFER ESRs will be highly competitive on the job market and much in demand. In particular, crystallography and biased signalling pharmacology of G protein-coupled receptors (e.g. 5-HT2A) are new and highly active research fields, today mastered by only a very few research groups worldwide. The timing and location of SAFER are particularly opportune, taking advantage of the new synchrotron MAX IV in Lund, Sweden, which is world leading for the study of challenging crystals. SAFER will seek to exploit innovation opportunities from novel molecular mechanisms, ligands, and crystal structures. The results will be integrated into a public community resource, GPCRdb, giving a unique potential to achieve community impact and long-term sustainability.

 Deliverables

List of deliverables.
2nd report on dissemination activities Documents, reports 2019-10-03 18:10:31
SAFER web site Websites, patent fillings, videos etc. 2019-07-24 18:15:34
1st report on dissemination activities Documents, reports 2019-07-24 18:15:34

Take a look to the deliverables list in detail:  detailed list of SAFER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More